NextLife Sciences, Inc. is a company that specializes in the development of innovative medical devices and technologies aimed at improving healthcare outcomes. Their focus is on creating solutions that address unmet clinical needs in various medical fields.

Luke Fox

NextLife Sciences, Inc.

NEXT Life Sciences is a medical device company that plans to deliver the first male contraceptive solution that is non-hormonal, long lasting, and reversible.

Particular Ventures

StartUp Health

NEXT Life Sciences, Inc.

In addition to NBC News coverage last week, we also had Arizona's Family CBS News tour our Flagstaff lab with our Chief Science Officer, Robert S. Kellar, Ph.D., where he and the team are hard at work optimizing and testing Plan A™!

Dr. Kellar shared, “Having the ability to develop new technology that gives not just men but partners, couples, some other options to consider in family planning is a really big deal.” With that importance being highlighted by our CEO L.R. Fox as "[enabling] people to proactively plan when they’re going to get pregnant.” 

We were also excited to see this news featured on Microsoft Start! You can catch the coverage at the link here: https://buff.ly/3JhDoqO

This week, 12 News (KPNX-TV, NBC) Arizona visited our Flagstaff lab with our Chief Science Officer, Robert S. Kellar, Ph.D., for an in-person look at Plan A™ and interviewed our CEO L.R. Fox about the skyrocketing interest we're seeing in male birth control!

Catch the coverage in full here: https://buff.ly/3Q2gqro

Birth control has disproportionately fallen on women... but now male contraception is in demand. In this week's Future Pulse from POLITICO, Ruth Reader sat down with our CEO L.R. Fox to chat about Plan A™ and the future of male contraception.

Read the interview on POLITICO here: https://buff.ly/3TMzqv4

Our CEO L.R. Fox sat down this week with Will Pavia from The Times for a closer look at his journey as an entrepreneur and to share more about his vision for Plan A & the future of #malebirthcontrol 

You can read the full article on The Times here: https://buff.ly/3PFyffM!

Have you ever wondered what it looks like in the labs where our leading scientists are making breakthroughs in male contraception? 

Melissa Sevigny, a reporter with KNAU, Arizona’s NPR affiliate, toured our Flagstaff lab where we’re working on Plan A, the reversible, long-lasting birth control for men:

“The goal is ten years of protection with one injection, reversible at any time with a second injection that dissolves the material and flushes it out. It’s called a LARC – Long Acting, Reversible Contraception. NEXT Life says it’s the holy grail of birth control.

L.R. Fox, the NEXT Life Sciences, Inc. CEO, sees a desperate need for products like Plan A, which he intends to bring to human clinical trials within the year. ‘The human right to choose when and if to have a child, is so fundamental, and yet is lacking in every single country, even the most industrialized countries in the world,’ Fox says.

For him, this issue is personal. ‘Coming from foster care myself, seeing the devastating impact of unplanned pregnancies, I chose to get a vasectomy,’ Fox says. ‘It’s a burden that I carry every day, knowing that I might not be able to ever have a child, because Plan A didn’t exist and wasn’t an option for me.’

And there are plenty of signs that Fox isn’t alone in wanting more choices. Though Plan A isn’t yet on the market, fifty thousand people have signed up for the interest list.”

Give the full piece a listen here: https://buff.ly/3PyASjA 

And learn more about the future of family planning here: PlanAforMen.com

We are extremely grateful and excited to announce that NEXT Life Sciences, Inc. has entered into a partnership with Male Contraceptive Initiative to receive a grant of $400K to support clinical trial research toward Plan A™!

Male Contraceptive Initiative (MCI), is the largest 501(c)(3) non-profit in the world dedicated to advancing male contraception. They accomplish their vision, “Reproduction Autonomy for All”, by bringing new male contraceptives to market through direct funding, technical support, research, and advocacy. This investment from MCI will help accelerate our team's progress toward giving men equitable access to participate in family planning with an option like Plan A™.

MCI Executive Director Heather Vahdat, MPH, shared: “The number of men and their partners expressing the desire for male contraceptive options continues to increase, and part of MCI’s dedication to accelerating product development includes thinking proactively about how to ensure a variety of delivery options. We are pleased to be able to get behind the talent and energy of NEXT Life Sciences in order to achieve a real vision for a shared contraceptive future.”

You can read more about this grant and our partnership in the article on AP News here: https://buff.ly/49BLNB8

Metric
Company Name	NextLife Sciences, Inc.
Symbol
MSH ID	ORG:NEXTLIFESCIENCES
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Medical Devices and Healthcare Technology
Country
Stage	Seed
Employee Count	8
Website	nextlifesciences.org
LinkedIn	next-life-sciences
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	108
Web Traffic Growth	-0.88
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ORG:NEXTLIFESCIENCES

NextLife Sciences, Inc.

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue